PriceTargets.com logo

LivaNova - LIVN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $69.17
  • Forecasted Upside: 38.20%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$50.05 As of 11/20/2024 01:00 AM ET
▼ -1.31 (-2.55%)

This chart shows the closing price for LIVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LivaNova Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIVN

Analyst Price Target is $69.17
▲ +38.20% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for LivaNova in the last 3 months. The average price target is $69.17, with a high forecast of $75.00 and a low forecast of $61.00. The average price target represents a 38.20% upside from the last price of $50.05.

This chart shows the closing price for LIVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in LivaNova. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
10/31/2024MizuhoLower TargetOutperform ➝ Outperform$80.00 ➝ $70.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
10/31/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$66.00 ➝ $72.00
10/4/2024The Goldman Sachs GroupInitiated CoverageBuy$65.00
9/17/2024Baird R WUpgradeHold ➝ Strong-Buy
9/17/2024Robert W. BairdUpgradeNeutral ➝ Outperform$55.00 ➝ $66.00
8/28/2024Robert W. BairdReiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00
8/1/2024Robert W. BairdLower TargetNeutral ➝ Neutral$57.00 ➝ $55.00
7/31/2024Needham & Company LLCBoost TargetBuy ➝ Buy$72.00 ➝ $75.00
7/25/2024Stifel NicolausBoost TargetBuy ➝ Buy$70.00 ➝ $72.00
6/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/2/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$58.00 ➝ $66.00
5/2/2024MizuhoBoost TargetBuy ➝ Buy$75.00 ➝ $80.00
5/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00
3/27/2024MizuhoReiterated RatingBuy ➝ Buy$75.00
3/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00
2/26/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$57.00 ➝ $61.00
2/22/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$56.00 ➝ $62.00
2/21/2024Needham & Company LLCBoost TargetBuy ➝ Buy$62.00 ➝ $72.00
2/20/2024MizuhoUpgradeNeutral ➝ Buy$60.00 ➝ $70.00
11/17/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$62.00
10/23/2023Needham & Company LLCLower TargetBuy ➝ Buy$71.00 ➝ $62.00
9/6/2023HSBCInitiated CoverageHold$52.00
7/27/2023MizuhoBoost Target$53.00 ➝ $60.00
7/27/2023Robert W. BairdBoost Target$56.00 ➝ $62.00
7/27/2023BarclaysBoost TargetEqual Weight$51.00 ➝ $57.00
7/18/2023Robert W. BairdInitiated CoverageNeutral$56.00
7/17/2023MizuhoBoost Target$48.00 ➝ $53.00
5/8/2023BarclaysBoost Target$45.00 ➝ $51.00
4/17/2023Needham & Company LLCReiterated RatingBuy$77.00
4/13/2023MizuhoInitiated CoverageNeutral$48.00
4/11/2023BarclaysLower Target$62.00 ➝ $45.00
12/21/2022BarclaysInitiated CoverageEqual Weight$62.00
11/23/2022The Goldman Sachs GroupLower TargetBuy$73.00 ➝ $63.00
11/2/2022Piper SandlerLower Target$94.00 ➝ $84.00
11/2/2022Needham & Company LLCLower TargetBuy$88.00 ➝ $77.00
8/16/2022The Goldman Sachs GroupLower TargetBuy$85.00 ➝ $73.00
8/4/2022Needham & Company LLCLower TargetBuy$106.00 ➝ $88.00
5/5/2022Piper SandlerLower Target$104.00 ➝ $99.00
4/5/2022Wolfe ResearchInitiated CoverageOutperform$95.00
2/24/2022UBS GroupUpgradeNeutral ➝ Buy$96.00
2/24/2022Needham & Company LLCLower TargetBuy$120.00 ➝ $106.00
12/3/2021Needham & Company LLCReiterated RatingBuy$119.00
12/3/2021The Goldman Sachs GroupInitiated CoverageBuy$108.00
11/3/2021Piper SandlerBoost TargetIn-Line ➝ Overweight$100.00 ➝ $105.00
11/3/2021Needham & Company LLCBoost TargetBuy$117.00 ➝ $120.00
8/20/2021Needham & Company LLCBoost TargetBuy$104.00 ➝ $117.00
8/17/2021Robert W. BairdBoost TargetOutperform$100.00 ➝ $105.00
7/20/2021Needham & Company LLCUpgradeHold ➝ Buy$93.00
6/7/2021Needham & Company LLCReiterated RatingHold
6/1/2021Piper SandlerLower TargetOverweight$99.00 ➝ $98.00
4/29/2021Robert W. BairdBoost TargetOutperform$85.00 ➝ $100.00
4/28/2021Piper SandlerBoost Target$92.00 ➝ $99.00
4/13/2021Piper SandlerBoost TargetOverweight$81.00 ➝ $92.00
3/9/2021Berenberg BankReiterated RatingBuy ➝ Hold$84.00
3/4/2021Needham & Company LLCReiterated RatingHold
3/3/2021Berenberg BankDowngradeBuy ➝ Hold$84.00
2/24/2021Piper SandlerBoost TargetOverweight$73.00 ➝ $81.00
1/12/2021Piper SandlerBoost TargetOverweight$70.00 ➝ $73.00
1/5/2021Needham & Company LLCDowngradeBuy ➝ Hold
12/15/2020Piper SandlerBoost TargetOverweight$63.00 ➝ $70.00
10/29/2020Piper SandlerBoost TargetOverweight$60.00 ➝ $63.00
10/21/2020Robert W. BairdBoost TargetOutperform$55.00 ➝ $65.00
9/1/2020Robert W. BairdInitiated CoverageOutperform$55.00
7/29/2020Piper SandlerLower TargetPositive ➝ Overweight$65.00 ➝ $60.00
7/29/2020Needham & Company LLCLower TargetBuy$76.00 ➝ $68.00
6/26/2020Needham & Company LLCLower TargetBuy$84.00 ➝ $76.00
4/30/2020UBS GroupLower TargetNeutral$70.00 ➝ $57.00
4/29/2020Piper SandlerLower TargetOverweight$80.00 ➝ $65.00
3/24/2020Stifel NicolausLower TargetBuy$80.00 ➝ $40.00
2/27/2020Berenberg BankReiterated RatingBuy$114.00
11/25/2019Stifel NicolausBoost TargetBuy$80.00 ➝ $90.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 10 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 4 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 15 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 13 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 15 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 15 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

LivaNova logo
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $50.05
Low: $49.98
High: $51.75

50 Day Range

MA: $51.96
Low: $47.45
High: $53.83

52 Week Range

Now: $50.05
Low: $42.75
High: $64.47

Volume

395,983 shs

Average Volume

615,608 shs

Market Capitalization

$2.72 billion

P/E Ratio

119.17

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of LivaNova?

The following Wall Street analysts have issued reports on LivaNova in the last year: Baird R W, Barclays PLC, Mizuho, Needham & Company LLC, Robert W. Baird, Stifel Nicolaus, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for LIVN.

What is the current price target for LivaNova?

0 Wall Street analysts have set twelve-month price targets for LivaNova in the last year. Their average twelve-month price target is $69.17, suggesting a possible upside of 38.2%. Needham & Company LLC has the highest price target set, predicting LIVN will reach $75.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $61.00 for LivaNova in the next year.
View the latest price targets for LIVN.

What is the current consensus analyst rating for LivaNova?

LivaNova currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LIVN will outperform the market and that investors should add to their positions of LivaNova.
View the latest ratings for LIVN.

What other companies compete with LivaNova?

Other companies that are similar to LivaNova include Haemonetics, Natus Medical, Outset Medical, Masimo and Penumbra. Learn More about companies similar to LivaNova.

How do I contact LivaNova's investor relations team?

LivaNova's physical mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company's listed phone number is 442033250660 and its investor relations email address is [email protected]. The official website for LivaNova is www.livanova.com. Learn More about contacing LivaNova investor relations.